No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
510 (estimated)
Sponsor
Immuneering Corporation · Industry
Who this trial is looking for
This trial is looking for adults with advanced pancreatic cancer. Participants will receive a combination treatment to see how effective and safe it is compared to standard treatment.
Are You a Good Fit for This Trial?
You may be able to join if
I am at least 18 years old
I have been diagnosed with metastatic pancreatic adenocarcinoma in the last 12 weeks
I have a performance status of 0 or 1
I have not received any previous systemic anti-cancer therapy
I have measurable disease with at least one target lesion
I have adequate organ and liver function
You may not be able to join if
I cannot swallow oral medications
I have a different type of pancreatic cancer
I have only locally advanced pancreatic disease
I have untreated or worsening brain metastases
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Must be ≥18 years of age
* Must have confirmed diagnosis according to AJCC staging as follows:
* Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Participants must be treatment…
Inclusion Criteria:
* Must be ≥18 years of age
* Must have confirmed diagnosis according to AJCC staging as follows:
* Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Participants must be treatment naive as follows:
* First-line PDAC participants will have received no previous systemic anti-cancer therapy
* Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria
* Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values
Exclusion Criteria:
* Inability to swallow oral medications
* Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
* Participants with only locally advanced disease
* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
